Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tigulixostat

Phase 3Small molecule

IInnovent Biologics Technology Limited (Shanghai R&D Center)

Tigulixostat is one of 26 small molecule programs targeting Gout. It is currently in Phase 3.

1

Indications

4

Total Trials

1

Active Trials

25

Competitors

Pipeline

Status by Indication[3][1]

Indication

GoutActive, not recruiting

GoutPhase 3

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Gout

#DrugCompanyPhaseTrials

Uloric

Zyloprim

Jazz Pharmaceuticals

Colcrys

Jazz Pharmaceuticals

Aleve

Jazz Pharmaceuticals

Trexall

Jazz Pharmaceuticals

Prevacid

Otezla

Cellcept

Glucophage

Rayos

RRoxane Laboratories

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Gout

NCT07414394

Clinical

Trials by Indication[1]

Gout3 trials

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

Completed·LLG Chem·Phase 3·NCT05586958·354 enrolled

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Completed·LLG Chem·Phase 3·NCT05586971·2,202 enrolled

A Randomized, Double-Blind, Double-Dummy, Multi-Center, Phase III Study Comparing the Efficacy and Safety of Tigulixostat (IBI128) and Febuxostat in Chinese Subjects With Gout

Active, not recruiting·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 3·NCT07414394·600 enrolled

Tics1 trial

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

Completed·LLG Chem·Phase 1·NCT06189404·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tigulixostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tigulixostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tigulixostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innovent Biologics Technology Limited (Shanghai R&D Center) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInnovent Biologics Technology Limited (Shanghai R&D Center)

Related News